BioAge Labs, Inc (BIOA) - Total Liabilities
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has total liabilities worth $27.63 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioAge Labs, Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how BioAge Labs, Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of BioAge Labs, Inc to evaluate short-term liquidity relative to the company's equity base.
BioAge Labs, Inc Competitors by Total Liabilities
The table below lists competitors of BioAge Labs, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Barclays PLC
LSE:BARC
|
UK | GBX1.62 Trillion |
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
China | CN¥2.95 Billion |
|
Suning Universal Co Ltd
SHE:000718
|
China | CN¥3.96 Billion |
|
D-MARKET E.S.+T.SP.ADR/1B
F:8WZ
|
Germany | €34.93 Billion |
|
Revolve Group LLC
NYSE:RVLV
|
USA | $261.05 Million |
|
Sheela Foam Limited
NSE:SFL
|
India | Rs20.90 Billion |
|
Beijing Dataway Horizon Co. Ltd
SHE:301169
|
China | CN¥176.90 Million |
|
Sats ASA
OL:SATS
|
Norway | Nkr8.18 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down BioAge Labs, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioAge Labs, Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioAge Labs, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioAge Labs, Inc (2013–2024)
The table below shows the annual total liabilities of BioAge Labs, Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $35.11 Million | -82.39% |
| 2023-12-31 | $199.32 Million | +41.37% |
| 2022-12-31 | $140.99 Million | +195.81% |
| 2017-12-31 | $47.66 Million | -57.76% |
| 2016-12-31 | $112.84 Million | +16.65% |
| 2015-12-31 | $96.73 Million | +1.92% |
| 2014-12-31 | $94.91 Million | +93.42% |
| 2013-12-31 | $49.07 Million | -- |
About BioAge Labs, Inc
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment o… Read more